Skip to main content
Monday, November 16, 2026Nov 16

Fury over drug price spikes rising, but increases aren’t new

FILE - In this June 14, 2011 file photo, various prescription drugs move along the automated pharmacy assembly line at Medco Health Solutions in Willingboro, N.J. Patients and politicians have been voicing outrage since it became public this week that a small drug company bought rights to an old drug and quickly raised its price more than 5,000 percent. But such "price gouging," as some politicians and other critics call it, has happened increasingly over the last few years. It could become more common because of decreasing industry competition and other factors. (AP Photo/Matt Rourke, File)
FILE - In this June 14, 2011 file photo, various prescription drugs move along the automated pharmacy assembly line at Medco Health Solutions in Willingboro, N.J. Patients and politicians have been voicing outrage since it became public this week that a small drug company bought rights to an old drug and quickly raised its price more than 5,000 percent. But such "price gouging," as some politicians and other critics call it, has happened increasingly over the last few years. It could become more common because of decreasing industry competition and other factors. (AP Photo/Matt Rourke, File)

TRENTON, N.J. (AP) – Hillary Clinton was among the patients and politicians who voiced outrage this week after it became public that the price of a 62-year-old drug used to treat a life-threatening infection had been raised by more than 5,000 percent.

But exorbitant drug price hikes like that have happened increasingly over the last few years. And they could become even more common because of decreasing competition in the pharmaceutical industry, among other factors.

The issue was brought to light after a Sunday article on drug price increases by The New York Times.

The story featured Turing Pharmaceuticals, a startup that paid Impax Laboratories $55 million in August for rights to Daraprim. It’s the only approved treatment for a rare parasitic infection called toxoplasmosis that mainly strikes pregnant women, cancer patients and AIDS patients.

Turing’s CEO, former hedge fund manager Martin Shkreli, soon raised Daraprim’s price from $13.50 to $750 per pill.